Polarean Imaging plc, the medical imaging technology company, announces that the US Food and Drug Administration (FDA) has granted approval for its drug device combination product, Xenoview. Xenoview, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in […]

The post US FDA approves Polarean Imaging’s drug device combination product, Xenoview first appeared on World Pharma Today.